Sunday, August 9, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Quantum Stocks Slump Deepens as IonQ Touches New Low Following US Executive Orders

Rodolfo Hanigan by Rodolfo Hanigan
July 17, 2026
in AI & Quantum Computing, Nasdaq, Tech & Software, Trading & Momentum
0
IonQ Stock
0
SHARES
46
VIEWS
Share on FacebookShare on Twitter

The sell-off in quantum computing shares has intensified, with IonQ falling to a fresh 2026 low on July 16 as the sector continues to digest the implications of two far-reaching executive orders signed by President Trump last month. The stock closed at $35.025, down 6.6% on the day after briefly dipping to $34.67, and has shed roughly 37% over the past 30 days. The relative strength index has sunk to 26.1, firmly in oversold territory, signaling how rapidly investor sentiment has soured on the quantum computing specialist.

The broader context for the rout lies in the regulatory landscape. On June 22, the White House launched the QC-ADDS initiative, setting a 2028 target for a fully functional quantum computer, while simultaneously mandating a migration to post-quantum cryptography with deadlines in 2030 and 2031 — a response to the threat of ‘harvest now, decrypt later’ attacks. According to multiple reports, quantum equities have fallen about 35% from the peaks they reached immediately after those announcements. IonQ’s own trajectory illustrates the decline: from a high above $60 earlier in the year to roughly $39 on July 13, followed by an additional 8% drop on July 16. The pain is sector-wide — Rigetti Computing has lost 29% and D-Wave Quantum 27.8% over the same 30-day window — but IonQ has been the hardest hit.

Compounding the regulatory headwind, the distribution of $2.013 billion in CHIPS Act funding to nine quantum firms on May 21 has recalibrated investor expectations. IBM received the largest single allocation — $1 billion for a chip foundry in Albany — signaling that government support is spreading broadly rather than concentrating on a few perceived leaders. That shift in funding architecture has prompted a more selective approach to valuations, dampening the earlier euphoria that had lifted stocks across the quantum universe.

Should investors sell immediately? Or is it worth buying IonQ?

Amid this sector turbulence, IonQ’s own financial picture is a study in contrasts. The company smashed revenue estimates for the first quarter, reporting $64.67 million — a 754.7% surge year-over-year and well above the consensus forecast of $49.75 million. Management also raised its full-year revenue guidance by $25 million to a range of $260–$270 million, and noted the first-ever sale of a 256-qubit system. Yet the bottom line disappointed: a GAAP net loss per share of $0.34 versus expectations of a $0.26 loss, reflecting an operating loss of $271.5 million. The headline net gain of $805.4 million was almost entirely due to a non-cash gain on convertible notes. Analysts polled by Zacks now expect a full-year loss of $1.07 per share on revenue of $267.45 million, and the stock currently carries a Zacks Rank #3 (Hold).

Insider activity has added to the negative tone. Over the past three months, company executives sold a total of 13,102 shares valued at $701,489. In June alone, board member John Raymond disposed of 3,815 shares at $55.01 each, and Gabrielle Toledano sold 2,757 shares at the same price — both well above the current market level. On the options market, bearish bets are piling up: some 199,216 put contracts changed hands on July 16, a 130% surge above the average daily volume. Institutional investors including Vanguard and State Street, however, have been adding to their positions during the same period.

Despite the severe correction, the analyst community remains broadly constructive. The consensus rating is ‘Moderate Buy’ with a median price target of $69.88 — nearly double the current share price. That wide gap between market price and analyst expectations captures the tension between near-term regulatory uncertainty and the long-term growth narrative that IonQ continues to articulate through its expanding revenue base and $470 million remaining performance obligations. The next test for the stock will come on August 5, when the company reports second-quarter results. With the sector already under intense scrutiny, any miss on guidance or margins could deepen the downturn, while a beat might begin to close the chasm between price and promise.

Ad

IonQ Stock: Buy or Sell?! New IonQ Analysis from August 8 delivers the answer:

The latest IonQ figures speak for themselves: Urgent action needed for IonQ investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 8.

IonQ: Buy or sell? Read more here...

Tags: IONQ
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Nvidia Stock
AI & Quantum Computing

Nvidia’s Latest Surge Is About More Than a Single Order

August 8, 2026
Applovin Stock
Analysis

AppLovin’s $40 Billion Wake-Up Call: When a 53% Growth Rate Isn’t Enough

August 8, 2026
Atlassian Stock
Earnings

Atlassian’s €128.80 Spike: A Profitability Inflection Point Arrives Just as Growth Slows

August 8, 2026
Next Post
Alibaba Stock

Netflix Flunks the Cash-Flow Test Wall Street Now Demands

FALLBACK Stock

Just 40 Minutes a Week: New Research Lowers Bar for Dementia-Preventing Exercise

Meta Stock

From Cost Center to Cloud: Meta's Infrastructure Avalanche Meets a Skeptical Analyst

Recommended

Biotechnology Stock Bull Market

Analyst Reiterates Buy Rating and 12 Price Target for Shattuck Labs Citing Promising Potential in Biotech Sector

2 years ago
Sangamo Therapeutics Stock

A Regulatory Milestone Sparks Renewed Interest in Sangamo Therapeutics

7 months ago
Diginex Stock

Leadership Shift at Diginex as ESG Software Founder Takes Helm

6 months ago
Novo Nordisk Stock

Novo Nordisk’s Bold Gambit: Price Cuts and Restructuring Amid Market Pressure

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Petrobras Delivers Record-Breaking Quarter, But Investors Keep Their Distance

Milan Fertility Clinic Suspended After Embryo Mix-Up Sparks Safety Reforms Across Europe

AppLovin’s $40 Billion Wake-Up Call: When a 53% Growth Rate Isn’t Enough

Atlassian’s €128.80 Spike: A Profitability Inflection Point Arrives Just as Growth Slows

Amazon’s Three-Trillion-Dollar Moment: A Founder’s Exit, a $220 Billion Wager, and the Fine Print Behind the Record Numbers

The AI Payoff Shifts: Airbnb, SpaceX, and Crypto Show Their Hand

Trending

Novo Nordisk Stock
European Markets

Novo Nordisk’s Oral Push Marks a Sales Milestone as Trial Setbacks and Rival Pressure Keep the Spotlight on the Pipeline

by SiterGedge
August 8, 2026
0

Novo Nordisk is getting one piece of good news that is easy to count: Wegovy has now...

Nvidia Stock

Nvidia’s Latest Surge Is About More Than a Single Order

August 8, 2026
Plug Power Stock

Plug Power’s Balancing Act: Property Sales Fund the Present While Australia’s Hydrogen Hub Points to the Future

August 8, 2026
Petrobras Stock

Petrobras Delivers Record-Breaking Quarter, But Investors Keep Their Distance

August 8, 2026
FALLBACK Stock

Milan Fertility Clinic Suspended After Embryo Mix-Up Sparks Safety Reforms Across Europe

August 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Novo Nordisk’s Oral Push Marks a Sales Milestone as Trial Setbacks and Rival Pressure Keep the Spotlight on the Pipeline
  • Nvidia’s Latest Surge Is About More Than a Single Order
  • Plug Power’s Balancing Act: Property Sales Fund the Present While Australia’s Hydrogen Hub Points to the Future

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com